Palliative care of patient with decompensated liver cirrhosis
Abstract
In this article a case of a patient with decompensated liver cirrhosis in whom an effective pain management was introduced with a significant reduction of pruritus intensity was submitted. Because of the liver insufficiency the care for cancer patients require a more intense monitoring regarding symptomatic treatment and sometimes causes necessity of resignation from some drugs administration. Even more caution is required during palliative treatment of patients diagnosed with decompensated liver cirrhosis. Schemes of the treatment of decompensated liver cirrhosis comprise many drugs, which are not being used in everyday clinical practice in palliative medicine. The application of these drugs in a depicted patient provided a significant improvement in efficacy of symptom management. Concurrently significant contraindications appeared for the use of drugs, which could be used in patients without liver cirrhosis
Keywords: liver cirrhosishepatocelular carcinomapurituspaliative careend-of-life-care
References
- Soleimanpour H, Safari S, Shahsavari Nia K, et al. Opioid Drugs in Patients With Liver Disease: A Systematic Review. Hepat Mon. 2016; 16(4): e32636.
- Pierre V, Johnston CK, Ferslew BC, et al. Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. CPT Pharmacometrics Syst Pharmacol. 2017; 6(5): 331–339.
- Baumann AJ, Wheeler DS, James M, et al. Benefit of Early Palliative Care Intervention in End-Stage Liver Disease Patients Awaiting Liver Transplantation. J Pain Symptom Manage. 2015; 50(6): 882–886.e2.
- Boyd K, Kimbell B, Murray S, et al. Living and dying well with end-stage liver disease: time for palliative care? Hepatology. 2012; 55(6): 1650–1651.
- Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1): S35–S50.
- Krajowy Rejestr Nowotworów. http://onkologia.org.pl/dane-metodologia/ (2016).
- Juszczyk J. Choroby wątroby. In: Juszczyk J. ed. Interna Szczeklika. Medycyna Praktyczna, Kraków 2016: 1111–4.
- Bai M, Yang Z, Qi X, et al. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013; 28(5): 783–792.
- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2): 715–735.
- Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol. 2017; 23(19): 3418–3426.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2): 237–267.
- Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006; 12(7): 1125–1128.
- Bachs L, Parés A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992; 102(6): 2077–2080.
- Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007; 45(3): 666–674.
- Imani F, Motavaf M, Safari S, et al. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon. 2014; 14(10): e23539.
- Saab S, Konyn PG, Viramontes MR, et al. Limited Knowledge of Acetaminophen in Patients with Liver Disease. J Clin Transl Hepatol. 2016; 4(4): 281–287.
- Haberer JP, Schoeffler P, Couderc E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982; 54(12): 1267–1270.
- Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984; 12(5): 577–581.
- Reddy L, Krajnik M, Zylicz Z. Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. J Pain Symptom Manage. 2007; 34(5): 455–456.
- Jin SJ, Jung JY, Noh MH, et al. The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. Clin Pharmacol Ther. 2011; 90(3): 423–431.
